Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of... Read More